Resetting Balance, Restoring Health

At Equillium, we leverage deep understanding of immunology and its role in disease to pioneer new products for severe autoimmune and inflammatory disorders.

About Itolizumab

Itolizumab is being developed in multiple severe immuno-inflammatory diseases.

07-12-2021

Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

06-11-2021

Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

View All

Clinical Trials

Clinical trials in acute Graft-Versus-Host Disease (aGVHD), asthma, and SLE / lupus nephritis are actively enrolling patients.

Restoring Balance to the Immune System

Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need.

About Itolizumab

Itolizumab is being developed in multiple severe immuno-inflammatory diseases.

Clinical Trials

Our EQUALISE study is now enrolling people with lupus or lupus nephritis.

Featured News

Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

Life is all about balance.

Bringing treatments designed to restore the balance of the immune system to patients who hope to restore the balance in their lives.

Our Science

When life hangs in the balance.

Equillium is actively recruiting individuals to participate in clinical trials for acute graft-versus-host disease (aGVHD), uncontrolled asthma, and lupus nephritis.

Clinical Trials